Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025

Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs [3] - The company's lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell therapy derived from the bone marrow of young, healthy adult donors [3] - Lomecel-B™ has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [3] Pipeline and FDA Designations - Longeveron is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty [3] - The HLHS program has received three important FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [3] - The Alzheimer's disease program has received two FDA designations: Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [3] Upcoming Events - Longeveron will participate in the Emerging Growth Virtual Conference on February 18-19, 2025, with a presentation scheduled for February 19, 2025, from 3:10 to 3:20 p.m. ET [1] - The webcast for the conference presentation will be accessible on the company's website, with a replay available for 180 days post-conference [1]